153 related articles for article (PubMed ID: 29743905)
1. Intravenous N-acetylcysteine for the PRevention Of Contrast-induced nephropathy - a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial.
Biernacka-Fiałkowska B; Szuksztul M; Suślik W; Dzierwa K; Tekieli Ł; Kostkiewicz M; Podolec P; Pieniążek P
Postepy Kardiol Interwencyjnej; 2018; 14(1):59-66. PubMed ID: 29743905
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
6. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
7. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
[TBL] [Abstract][Full Text] [Related]
8. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
9. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
10. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
[TBL] [Abstract][Full Text] [Related]
11. N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study.
Staniloae CS; Doucet S; Sharma SK; Katholi RE; Mody KR; Coppola JT; Solomon R
J Interv Cardiol; 2009 Jun; 22(3):261-5. PubMed ID: 19490358
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
13. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
[TBL] [Abstract][Full Text] [Related]
14. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
[TBL] [Abstract][Full Text] [Related]
17. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
[TBL] [Abstract][Full Text] [Related]
18. Preventive effect of N-acetylcysteine on contrast-induced nephropathy following coronary angiography and angioplasty.
Kamiyama N; Ogawa R; Hamada H; Ohno T; Asano R; Umemura J; Yoshida H
Yakugaku Zasshi; 2008 Sep; 128(9):1333-9. PubMed ID: 18758148
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
[TBL] [Abstract][Full Text] [Related]
20. N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial.
Heguilén RM; Liste AA; Payaslian M; Ortemberg MG; Albarracín LM; Bernasconi AR
Clin Exp Nephrol; 2013 Jun; 17(3):396-404. PubMed ID: 23138396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
